Design Therapeutics Inc
NASDAQ:DSGN
Design Therapeutics Inc
NASDAQ:DSGN
Price:
4.77 USD
1.71%
Updated:
May 10, 2024
Design Therapeutics Inc
Selling, General & Administrative
|
Design Therapeutics Inc
Selling, General & Administrative Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Selling, General & Administrative Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Design Therapeutics Inc
NASDAQ:DSGN
|
Selling, General & Administrative
-$21.1m
|
CAGR 3-Years
-104%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Selling, General & Administrative
-$12.7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Selling, General & Administrative
-$6.1B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-13%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Selling, General & Administrative
-$6.7B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Selling, General & Administrative
-$1.1B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-12%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Selling, General & Administrative
-$2.7B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-23%
|
See Also
What is Design Therapeutics Inc's Selling, General & Administrative?
Selling, General & Administrative
-21.1m
USD
-21.1m
USD
Based on the financial report for Dec 31, 2023, Design Therapeutics Inc's Selling, General & Administrative amounts to -21.1m USD.
What is Design Therapeutics Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 3Y
-104%
-104%
Over the last year, the Selling, General & Administrative growth was -11%. The average annual Selling, General & Administrative growth rates for Design Therapeutics Inc have been -104% over the past three years .
You don't have any saved screeners yet
